From molecules to photons
Optomics® combines a proprietary AI and Photonics approach to rigorously generate massive amounts of high-dimensional digital biological fingerprints - “a digital twin” - from minimum volumes of serum of plasma.
Spectral
acquisition
A minimal volume of serum or plasma is acquired from a standard clinical blood draw: no special sample preparation, no additional patient procedures.
The sample is then analyzed by Optomics®’ proprietary spectral technology, which illuminates the sample and captures a rich, multi-dimensional optical response across thousands of data points.
The physical measurement takes under 30 seconds. The sample is preserved intact for downstream use.
<5m
TIME TO RESULT · SAMPLE PRESERVED INTACT
AI-powered
fingerprinting
The raw spectral signal is processed by iLOF's proprietary AI engine, which translated it into a high-dimensional biological twin: the optical fingerprint.
Each fingerprint encodes thousands of subtle biological patterns, capturing system-level signals that reflect the integrated state of the sample across multiple biological axes simultaneously.
Fundamentally different from traditional -omics approaches. Optomics® captures the integrated signal - the whole, not the parts.
1000
Data points encoded per optical fingerprint
Matching
& scoring
The optical fingerprint is matched against iLOF continuously growing biomarker library. AI performs biologically meaningful pattern-matching against similar twins in the library, linking the individual’s signals to clinically validated disease signatures.
The output is a high-confidence pathological risk score: actionable, interpretable, and delivered within the clinical workflow.
Because the library grows continuously, model performance improves over time: earlier screening, higher specificity.
>90%
Accuracy
Built over six years across 50+ clinical sites in nine countries, the platform is the foundation for smarter clinical decision-making, faster trial execution, and more efficient drug development.
The library
A compounding
data advantage
At the core of Optomics® is a proprietary biomarker library assembled over six years of clinical research - spanning multiple disease areas, populations, and geographies. Every new digital twin acquired adds to a growing body of biological intelligence that continuously improves the platform’s pattern-recognition capabilities.
+10 000
Optical fingerprints in the library
Growing with every clinical partnership
7
Case studies
Across disease areas & geographies
+50
Clinical sites
Across nine countries
6 yrs
Library build
Continuous accumulation
Unlike AI platforms trained on publicly available datasets, the Optomics® library is proprietary, clinically validated, and tied to a physical measurement method that cannot be replicated without the spectroscopic instrument.
This creates a compounding moat: every clinical partnership adds twins, every fingerprints improves the model, and every model improvement expands the addressable indication set.
Validated performance
Alzheimer’s disease:
breaking the invasiveness barrier
Diagnosing Alzheimer’s currently requires lumbar punctures or expensive PET scans: both inaccessible at scale and prohibitively expensive for population screening. Optomics® changes that calculus.
From expensive PET scans to a plasma sample
By functioning as a rapid, label-free pre-screening layer in plasma, Optomics® filters out unlikely candidates before expensive confirmatory testing - protecting patients from unnecessary invasive procedures and reducing trial screening costs by up to 40%.
>90%
Specificity
Alzheimer’s pre-screen
<5m
Time to score
From acquisition to result
−40%
Screening cost
vs. PET scan pathway
−70%
Recruitment time
Clinical trial cohort build
In Alzheimer’s clinical trials, 80% of candidates are currently excluded only after costly, invasive tests. Optomics® moves that filter to the front of the pathway.
Platform-level performance
Across all indications, Optomics® is designed around six non-negotiable performance requirements.
Actionable intelligence with tangible outcomes
Decision-ready risk scoring
Converts spectral signals into pathological risk scores designed for clinical decision-making not raw data requiring expert interpretation.
Lower cost per diagnostic insight
Photonic acquisition at a fraction of imaging cost
Reduces the per-patient diagnostic spend by avoiding costly imaging and biopsy procedures for low-risk individuals.
Multiple clinical answers from a single test
Simultaneous multi-biomarker readout
A single measurement session yields independent risk outputs across multiple disease pathways, expanding clinical utility without added patient burden.
Reduces avoidable testing
Non-contact photonic measurement
Optomics® acquires its signal through light interaction with tissue — removing procedural risk, patient discomfort, and clinical barriers to testing.
Results in minutes, not days
Real-time AI inference pipeline
From signal acquisition to risk score, the full pipeline completes at point of care — compressing the diagnostic interval from days or weeks to a single clinical encounter.
Scalable and portable: built for global consistency
Cloud-enabled architecture, point-of-care ready
Cloud-native infrastructure ensures consistent performance from central lab to point-of-care setting - deployable across geographies without loss of model fidelity.
Two application vectors
What Optomics® delivers
A triage tool for smarter patient pathways
Optomics® operates as a two-step clinical filter: first, a safety-first screening layer that rules out disease for the majority, allowing low-risk patients to return to routine care with high confidence. Second, an evidence-based escalation layer that directs positive cases toward the right intervention, ensuring costly procedures are reserved for patients most likely to benefit.
OUTCOME
Fewer missed cases, fewer unnecessary tests, shorter time to definitive care.
See lung, Alzheimer’s & ovarian case studies →
Optimized stratification for faster trials
Powered by the digital twin library, Optomics® delivers an objective, high-confidence risk stratification score supporting cohort enrichment, accelerated eligibility, and reduced screen failure — compressing the diagnostic interval from months to days.
OUTCOME
Faster recruitment, improved cohort quality, more efficient study execution.
Explore trial applications →
IP & regulatory standing
Protected by design. Validated for clinical use.
Optomics® is built on a portfolio of intellectual property spanning the physical measurement layer, the AI processing architecture, and the brand protected across key markets.
The combination of proprietary spectral acquisition, a protected AI method, and a continuously growing clinical library creates a multi-layered defensibility structure that cannot be replicated through software alone.
CE marking of selected device components and ISO 13485 certification confirm that i operates at medical device quality standards.
.avif)
6
3
CE
ISO 13485
Ready to see Optomics® in action?
Explore how Optomics® creates value
Lung cancer · Alzheimer's · Ovarian cancer · Drug development
Read ths science behind Optomics®
Recruitment timelines, stratification scores, cohort quality - let's talk about your next study.
